Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

James Hadley

Otolaryngology Naples, FL Medical Doctor

NPI 1730112640 CMS profile 350292

6101 Pine Ridge Rd, Ste 1106, Naples, FL 34119

Open in the dashboard

General payments

$33,266

101 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, James Hadley of Naples, FL is reported in the CMS Open Payments database as having received $33,266 across 101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $208 5
2022 General $686 30
2021 General $275 13
2020 General $2,741 4
2019 General $29,356 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Hadley
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to James Hadley were reported at $0. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year James Hadley Otolaryngology median Middle half National median
2019 $29,356 $194 $82–$512 $163
2020 $2,741 $118 $42–$280 $114
2021 $275 $167 $63–$444 $132
2022 $686 $216 $84–$545 $149
2023 $208 $235 $93–$588 $160
2024 $0 $280 $111–$699 $164
2025 $0 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Regeneron Healthcare Solutions, Inc. $27,920 40 payments
  2. OptiNose US, Inc. $3,517 22 payments
  3. Genzyme Corporation $1,149 14 payments
  4. GlaxoSmithKline, LLC. $317 15 payments
  5. Sanofi-Aventis U.S. LLC $92 2 payments
  6. Allergan Inc. $84 1 payment
  7. Intersect ENT, Inc. $68 2 payments
  8. Arthrex, Inc. $45 1 payment
  9. Merck Sharp & Dohme Corporation $38 2 payments
  10. Stryker Corporation $20 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,517 4 payments
  2. Consulting Fee $8,640 2 payments
  3. Travel and Lodging $4,375 20 payments
  4. Honoraria $2,500 1 payment
  5. Food and Beverage $2,234 74 payments
Products named General payments · program years 2019–2023
  1. DUPIXENT Inflammation And Immunology $27,920 40 payments
  2. Xhance $3,517 22 payments
  3. DUPIXENT Immunology $738 3 payments
  4. DUPIXENT Immunology $503 13 payments
  5. NUCALA $317 15 payments
  6. BOTOX COSMETIC $84 1 payment
  7. SINUVA $68 2 payments
  8. PROPEL $45 1 payment
  9. MEDLINE INDUSTRIES, INC. $20 1 payment
  10. SYMBICORT $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record